Showing 4351-4360 of 5771 results for "".
- Aerie Pharmaceuticals Receives European Commission Approval for Glaucoma Treatment Roclandahttps://modernod.com/news/aerie-pharmaceuticals-receives-european-commission-approval-for-glaucoma-treatment-roclanda/2478740/Aerie Pharmaceuticals announced the European Commission (EC) has granted a marketing authorization for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of elevated IOP in adult patients with primary open-angle glaucoma or ocular hypertension for whom monoth
- Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Datahttps://modernod.com/news/graybug-vision-completes-treatment-phase-of-altissimo-trial-in-wet-amd-with-12-month-topline-data/2478738/Graybug Vision announced the last patient visit in its GB-102 phase 2b ALTISSIMO core trial (the 12-month treatment phase) in wet age-related macular degeneration (AMD). ALTISSIMO 12-month topline data are expected to be announced in the second quarter of 2021, with full results to b
- Ocular Therapeutix Promotes Michael Goldstein, MD, MBA, to President, Ophthalmologyhttps://modernod.com/news/ocular-therapeutix-promotes-michael-goldstein-md-mba-to-president-ophthalmology/2478733/Ocular Therapeutix announced the promotion of Michael Goldstein, MD, MBA, to the newly created position of President, Ophthalmology. Dr. Goldstein will continue to report to Antony Mattessich, Ocular’s President and Chief Executive Officer. With this promotion, Dr. Goldstein will be responsible f
- Haag-Streit Introduces Lenstar Myopia for Myopia Managementhttps://modernod.com/news/haag-streit-introduces-lenstar-myopia-for-myopia-management/2478732/Haag-Streit has announced the launch of Lenstar Myopia, a solution for myopia management and patient education. Lenstar Myopia consists of the Lenstar 900 optical biometer and the corresponding EyeSuite software, EyeSuite Myopia. EyeSuite Myopia uses the latest axial length growth curves f
- ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10https://modernod.com/news/proqr-completes-enrollment-of-its-pivotal-trial-of-sepofarsen-for-the-treatment-of-lca10/2478728/ProQR Therapeutics announced it has completed patient enrollment in its phase 2/3 Illuminate study of sepofarsen for the treatment of Leber Congenital Amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. With enrollment completed, topline results are expected in the first half (
- IACTA Pharmaceuticals and Pharmaleads to Develop the World’s First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Painhttps://modernod.com/news/iacta-pharmaceuticals-and-pharmaleads-to-develop-the-worlds-first-epithelial-protective-drug-harnessing-endogenous-analgesia-for-the-topical-treatment-of-acute-and-chronic-ocular-pain/2478730/IACTA Pharmaceuticals and Pharmaleads announced they have entered into licensing agreements with IACTA acquiring global rights to Pharmaleads’ Dual Enkephalinase Inhibitors (DENKI), a novel class of non-opioid compounds for the treatment of acute and chronic ocular pain. “With
- SIFI Launches Dry Eye Disease Device Synfohttps://modernod.com/news/sifi-launches-dry-eye-disease-synfo/2478726/SIFI announced the launch of Synfo, a novel medical device for dry eye disease. The new hypotonic formulation is a synergistic blend of two polymers—sodium hyaluronate and xanthan gum—and two osmoprotectants, betaine and glycine. In addition to moisturizing and lubricating, Synfo is design
- Volk Optical Releases ClearPod to Address Mask-Related Fogging During Fundus Examinationshttps://modernod.com/news/volk-optical-releases-clearpod-to-address-mask-related-fogging-during-fundus-examinations/2478724/Volk Optical announced the release their newest product, the ClearPod, which aims to solve the problem of mask-related fogging during fundus examinations. This patent-pending design has been created in collaboration with ophthalmologists Bradley Sacher, MD, a cataract specialist, and Jerem
- Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol for Reversal of Mydriasishttps://modernod.com/news/ocuphire-completes-enrollment-in-mira-2-phase-3-clinical-trial-investigating-nyxol-for-reversal-of-mydriasis/2478719/Ocuphire Pharma announced that it has completed enrollment earlier than expected in its MIRA-2 phase 3 registration clinical trial evaluating the safety and efficacy of Nyxol to reverse pharmacologically-induced mydriasis. “We are pleased to exceed our enrollment target and reach this impo
- Nicox’s Licensee Bausch + Lomb Launches Vyzulta in Mexicohttps://modernod.com/news/nicoxs-licensee-bausch-lomb-launches-vyzulta-in-mexico/2478720/Nicox announced that an affiliate of its licensee, Bausch + Lomb, has launched Vyzulta (latanoprostene bunod ophthalmic solution), 0.024% in Mexico. Approval was obtained in Mexico in January 2020. Vyzulta is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular